Related Experiment Video
Updated: Dec 25, 2025

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
Published on: February 15, 2019
Experimental gene therapies for the NCLs
Wenfei Liu1, Sophia-Martha Kleine-Holthaus2, Saul Herranz-Martin3
1UCL School of Pharmacy, University College London, UK.
Abstract:
The neuronal ceroid lipofuscinoses (NCLs), also known as Batten disease, are a group of rare monogenic neurodegenerative diseases predominantly affecting children. All NCLs are lethal and incurable and only one has an approved treatment available. To date, 13 NCL subtypes (CLN1-8, CLN10-14) have been identified, based on the particular disease-causing defective gene. The exact functions of NCL proteins and the pathological mechanisms underlying the diseases are still unclear. However, gene therapy has emerged as an attractive therapeutic strategy for this group of conditions. Here we provide a short review discussing updates on the current gene therapy studies for the NCLs.
More Related Videos
Related Concept Videos
Gene Therapy
In-vitro Mutagenesis

